| Citation: |
TAN Meijuan, YANG Shijie, XU Xiequn. A Bibliometric Analysis of Medullary Thyroid Carcinoma From 2000 to 2022[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 133-142. DOI: 10.12290/xhyxzz.2024-0146
|
To review the state of research on medullary thyroid carcinoma (MTC) over the past two decades, so as to offer a quick reference for understanding the current state and future trends in this field.
A computer was employed to search the Web of Science Core Collection database for MTC-related literature (types: articles and reviews) published between 2000 and 2022. VOS viewer 1.6.18 software was utilized to create collaboration network diagrams, heat distribution diagrams for high-yielding countries(with publication volume ≥90), research institutions (with publication volume ≥60), and authors (with publication volume ≥30), and high-frequency keyword clustering network diagrams. Cite Space 5.7.R5 software was employed to conduct cluster analysis and explosive keyword detection on co-cited literature.
A total of 4866 MTC related literature (3688 articles and 918 reviews) were obtained. Although the annual publication volume fluctuated, the overall trend showed a gradual increase. The 4866 articles are from 87 countries, involving 4250 research institutions, 21 016 authors, and 963 journals. The United States (1436 articles), MD Anderson Cancer Center at the University of Texas (139 articles), and Dralle H (Department of General Surgery at Halle Wittenberg University Hospital, 61 articles) were the countries, research institutions, and authors with the highest number of publications, respectively. High frequency keywords form four clusters: RET gene expression, prognostic factors, MTC clinical management, and MTC treatment. The keywords emerging explosively in recent years were management, survival, guideline, association, etc. The key areas of focus in highly cited literature were RET proto oncogene, targeted therapy, RET gene mutation, and so on.
In the past 20 years, MTC related research has shown a gradual upward trend, with developed countries led by the United States taking a leading position in this field. The current research hotspots are the treatment, diagnosis, application of inhibitors, and exploration of the pathogenesis of MTC.
| [1] |
Mohebati A, Shaha A R. Anatomy of thyroid and parathyroid glands and neurovascular relations[J]. Clin Anat, 2012, 25(1): 19-31. DOI: 10.1002/ca.21220
|
| [2] |
Xu S J, Han Y. The overdiagnosis of thyroid micropapillary carcinoma: the rising incidence, inert biological behavior, and countermeasures[J]. J Oncol, 2021, 2021: 5544232.
|
| [3] |
Jayasinghe R, Basnayake O, Jayarajah U, et al. Management of medullary carcinoma of the thyroid: a review[J]. J Int Med Res, 2022, 50(7): 3000605221110698. DOI: 10.1177/03000605221110698
|
| [4] |
Porter A, Wong D J. Perspectives on the treatment of advanced thyroid cancer: approved therapies, resistance mechanisms, and future directions[J]. Front Oncol, 2020, 10: 592202.
|
| [5] |
Tran B X, Pham T V, Ha G H, et al. A bibliometric analysis of the global research trend in child maltreatment[J]. Int J Environ Res Public Health, 2018, 15(7): 1456. DOI: 10.3390/ijerph15071456
|
| [6] |
Zhu X Q, Hu J Q, Deng S H, et al. Bibliometric and visual analysis of research on the links between the gut microbiota and depression from 1999 to 2019[J]. Front Psychiatry, 2020, 11: 587670.
|
| [7] |
Machens A, Lorenz K, Weber F, et al. Metastatic risk profile of microscopic lymphatic and venous invasion in medullary thyroid cancer[J]. Horm Metab Res, 2021, 53(9): 588-593. DOI: 10.1055/a-1559-3424
|
| [8] |
Machens A, Lorenz K, Weber F, et al. Exceptionality of distant metastasis in node-negative hereditary and sporadic medullary thyroid cancer: lessons learned[J]. J Clin Endocrinol Metab, 2021, 106(8): e2968-e2979. DOI: 10.1210/clinem/dgab214
|
| [9] |
Elisei R, Ciampi R, Matrone A, et al. Somatic RET indels in sporadic medullary thyroid cancer: prevalence and response to selpercatinib[J]. J Clin Endocrinol Metab, 2022, 107(8): 2195-2202. DOI: 10.1210/clinem/dgac325
|
| [10] |
Prete A, Gambale C, Cappagli V, et al. Chylous effusions in advanced medullary thyroid cancer patients treated with selpercatinib[J]. Eur J Endocrinol, 2022, 187(6): 905-915. DOI: 10.1530/EJE-22-0643
|
| [11] |
Guenter R, Patel Z, Chen H. Notch signaling in thyroid cancer[J]. Adv Exp Med Biol, 2021, 1287: 155-168.
|
| [12] |
Lou I, Odorico S, Yu X M, et al. Notch3 as a novel therapeutic target in metastatic medullary thyroid cancer[J]. Surgery, 2018, 163(1): 104-111. DOI: 10.1016/j.surg.2017.07.039
|
| [13] |
Jang S, Janssen A, Aburjania Z, et al. Histone deacetylase inhibitor thailandepsin-A activates Notch signaling and suppresses neuroendocrine cancer cell growth in vivo[J]. Oncotarget, 2017, 8(41): 70828-70840. DOI: 10.18632/oncotarget.19993
|
| [14] |
Arighi E, Borrello M G, Sariola H. RET tyrosine kinase signaling in development and cancer[J]. Cytokine Growth Factor Rev, 2005, 16(4/5): 441-467.
|
| [15] |
de Groot J W B, Links T P, Plukker J T M, et al. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors[J]. Endocr Rev, 2006, 27(5): 535-560. DOI: 10.1210/er.2006-0017
|
| [16] |
Wells S A, Asa S L, Dralle H, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma: the American Thyroid Association Guidelines Task Force on Medullary Thyroid Carcinoma[J]. Thyroid, 2015, 25(6): 567-610. DOI: 10.1089/thy.2014.0335
|
| [17] |
Wells S A, Gosnell J E, Gagel R F, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer[J]. J Clin Oncol, 2010, 28(5): 767-772. DOI: 10.1200/JCO.2009.23.6604
|
| [18] |
Schlumberger M J, Elisei R, Bastholt L, et al. Phase Ⅱ study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer[J]. J Clin Oncol, 2009, 27(23): 3794-3801. DOI: 10.1200/JCO.2008.18.7815
|
| [19] |
Dabelić N, Jukić T, Fröbe A. Medullary thyroid cancer-feature review and update on systemic treatment[J]. Acta Clin Croat, 2020, 59(Suppl 1): 50-59.
|
| [20] |
Ali F, Neha K, Chauhan G. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers[J]. Arch Pharm Res, 2022, 45(5): 309-327. DOI: 10.1007/s12272-022-01385-3
|
| [21] |
Kloos R T, Eng C, Evans D B, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association[J]. Thyroid, 2009, 19(6): 565-612. DOI: 10.1089/thy.2008.0403
|
| [22] |
Jassal K, Ravintharan N, Prabhakaran S, et al. Preopera-tive serum calcitonin may improve initial surgery for medullary thyroid cancer in patients with indeterminate cytology[J]. ANZ J Surg, 2022, 92(6): 1428-1433. DOI: 10.1111/ans.17690
|
| [23] |
Bartz-Kurycki M A, Oluwo O E, Morris-Wiseman L F. Medullary thyroid carcinoma: recent advances in identification, treatment, and prognosis[J]. Ther Adv Endocrinol Metab, 2021, 12: 20420188211049611. DOI: 10.1177/20420188211049611
|
| [24] |
Elisei R, Bottici V, Luchetti F, et al. Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10, 864 patients with nodular thyroid disorders[J]. J Clin Endocrinol Metab, 2004, 89(1): 163-168. DOI: 10.1210/jc.2003-030550
|
| [25] |
Workman A D, Soylu S, Kamani D, et al. Limitations of preoperative cytology for medullary thyroid cancer: Proposal for improved preoperative diagnosis for optimal initial medullary thyroid carcinoma specific surgery[J]. Head Neck, 2021, 43(3): 920-927. DOI: 10.1002/hed.26550
|
| [26] |
Thomas C M, Asa S L, Ezzat S, et al. Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines[J]. Curr Oncol, 2019, 26(5): 338-344. DOI: 10.3747/co.26.5539
|
| [27] |
Wong K K, Laird A M, Moubayed A, et al. How has the management of medullary thyroid carcinoma changed with the Advent of 18F-FDG and non-18F-FDG PET radiopharmaceuticals[J]. Nucl Med Commun, 2012, 33(7): 679-688. DOI: 10.1097/MNM.0b013e3283529bf7
|
| [28] |
Dudczak R, Traub-Weidinger T. PET and PET/CT in endocrine tumours[J]. Eur J Radiol, 2010, 73(3): 481-493. DOI: 10.1016/j.ejrad.2009.12.024
|
| [1] | ZHANG Shan, LIU Jie. Interpretation of NCCN Clinical Practice Guidelines for Primary Cutaneous Lymphomas (Version 1.2024) Based on the Current Diagnosis and Treatment Status of China[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1029-1037. DOI: 10.12290/xhyxzz.2024-0605 |
| [2] | LUO Fuchao, ZHANG Junhua, CHENG Peng, WU Jing, ZHONG Bin, LYU Bing, HUANG Guogang, LIU Yang, ZHANG Zexue, WEI Xiaohong. Clinical Application of Ultrasound-guided RISS Plane Block for Postoperative Analgesia After Minimally Invasive McKeown Esophagectomy: A Prospective Randomized Controlled Study[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(3): 624-631. DOI: 10.12290/xhyxzz.2023-0358 |
| [3] | ZHU He, WEN Bei, XU Li, HUANG Yuguang. Mechanism of Wnt5a on Keratinocyte Regulating MMP9 for CRPS-Ⅰ Peripheral Sensitization[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(2): 335-343. DOI: 10.12290/xhyxzz.2023-0551 |
| [4] | ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. DOI: 10.12290/xhyxzz.2023-0227 |
| [5] | LIU Yuan, ZHAO Lin. Update and Interpretation of 2022 National Comprehensive Cancer Network Clinical Practice Guidelines for Gastric Cancer[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(6): 999-1004. DOI: 10.12290/xhyxzz.2022-0271 |
| [6] | ZHANG Shan, LIU Zhaorui, LIU Jie. Relationship Between SerpinB9 and Tumors and Research Progress of SerpinB9 in Skin Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(5): 852-857. DOI: 10.12290/xhyxzz.2021-0805 |
| [7] | Qi JIN, Qin LUO, Zhi-hui ZHAO, Zhi-hong LIU. MicroRNA-21 in the Pathogenesis of Pulmonary Hypertension[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(4): 430-438. DOI: 10.3969/j.issn.1674-9081.2020.04.013 |
| [8] | Hao GUO, Wen-da WANG, Yi CAI, Yu-shi ZHANG. Progress in Research on MicroRNA in Tuberous Sclerosis Complex Related Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2017, 8(4-5): 283-288. DOI: 10.3969/j.issn.1674-9081.2017.05.017 |
Supported by: Beijing Renhe Information Technology Co., Ltd. 
Submit
Review
Office
Email Alert
RSS
DownLoad: